Incorporating GFAP into a panel of biomarkers enhances diagnostic accuracy for Alzheimer’s disease by providing additional insights into astrocytic activation and neuroinflammation, which are critical aspects of the disease’s pathology. Here, GFAP is linked to early-onset autosomal dominant Alzheimer disease.